Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Y-6 Sublingual Tablets for Acute Ischemic Stroke
NCT06138834Phase 2Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cilostazol and dexborneol in ischemic stroke (5 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of modified-Rankin scale score recovered to 0~1 at 90 days. Status: unknown.
02
Drugs
cilostazoldexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06138834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138834.